Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Sarcoma. 12 results shown below.

Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

[Complete title: A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 2537.00
Phase: I

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study To Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

[Complete title: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung]
Principal Investigator: Robin Jones
Study Number: 7008
Phase: II

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

[Complete title: The Effect of Antiangiogenic Therapy with Pazopanib Prior to Preoperative Chemotherapy for Subjects with Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging]
Principal Investigator: Robin Jones
Study Number: 7487
Phase: Pilot

European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99)
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS0331
Phase: III

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Principal Investigator: Doug Hawkins, MD
Study Number: ARST0531
Phase: III

Treatment of High Risk Renal Tumors; A Groupwide Phase II Study.
Principal Investigator: Doug Hawkins, MD
Study Number: AREN0321
Phase: II

Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Principal Investigator: Doug Hawkins, MD
Study Number: ARST0332
Phase: III

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
Principal Investigator: Robin Jones
Study Number: 20051530
Phase: III

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

[Complete title: A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide]
Principal Investigator: Robin Jones
Study Number: 20110545
Phase: III

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

[Complete title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma]
Principal Investigator: Robin Jones
Study Number: 20111252
Phase: III

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.